Brand Intelligence Graph
Company Overview
About eGenesis
eGenesis is developing gene-edited pig organs for human transplantation — xenotransplantation — using a 69-gene CRISPR editing protocol that simultaneously knocks out pig genes that trigger human rejection, adds human immune tolerance genes, and eliminates porcine endogenous retroviruses. The company received FDA clearance for its IND for EIGEN-2784 (a gene-edited pig kidney) for end-stage kidney disease, and its first transplant patient remained dialysis-free at more than 7 months post-transplant — the longest reported survival for a xenotransplantation recipient.
Business Model & Competitive Advantage
The 69-gene edit represents the most complex CRISPR modification ever applied to a large animal, developed over a decade of research at Harvard Medical School. The clinical trial now enrolling is pivotal: if positive results are sustained, it would establish gene-edited pig kidneys as a viable alternative to human donor organs — addressing the chronic shortage of 100,000+ patients on the US kidney transplant waiting list, of whom 13 patients die each day awaiting a kidney.
Competitive Landscape 2025–2026
eGenesis's approach is systematically addressing the three barriers to xenotransplantation: hyperacute rejection (pig galactose antigens), chronic rejection (human immune response), and the risk of porcine viral transmission (PERV elimination). The 69-gene protocol represents the most thorough published solution to all three barriers simultaneously, making eGenesis the most clinically advanced xenotransplantation program globally.
Key Differentiators
Emerging Innovator
eGenesis is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare eGenesis with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from eGenesis? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim eGenesis Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention eGenesis vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →